Tell a Friend


Legal Series: Understanding FDA’s Consent Form Requirements
   LIVE Webcast  


Event Details:                                                                                                                                                          

The Food and Drug Administration issued a new consent form requirement for certain FDA-regulated clinical trials effective this March 7, 2012. Consent forms of drugs, biological products or devices that are subject to FDA regulation are required to contain a specific statement provided by the FDA. The statement is required for applicable clinical trials initiated on or after March 7, 2012, the statement is intended to advise the participants that clinical trial information may be available on the database. The question now is how should the industry comply in a cost effective manner that does not compromise the integrity of the science.

The Knowledge Group has assembled a panel of key thought leaders and regulators to help health executives understand all the important issues with respect to this important topic. This live webcast is a must attend for all health executives who need to be in the know with respect to FDA's new consent form requirement. The panel will address the key issues and will answer the following main concerns:

Course Level: Intermediate
Prerequisite: None
Method Of Presentation: Group-Based-Internet
Developer: The Knowledge Group, LLC
Recommended CLE/CPE Hours: 1.75 - 2.0
Advance Preparation: Print and review course materials
Course Code: 124329
Course Fee: $299 (Please click here for details)


Featured Speakers for Legal Series: Understanding FDA’s Consent Form Requirements LIVE Webcast :

Agenda  (click here to view more)

Jarilyn Dupont , Director of Regulatory Policy,
FDA/Office of Policy

  • • The informed consent regulations (21 CFR 50.25(c)) require that informed consent documents and processes for applicable drug (including biological products) and device clinical trials include a specific statement that clinical trial information will be entered into the databank.
  • • Submission of certain clinical trial information, including certain results information, to is required by the Food and Drug Administration Amendments Act of 2007 (FDAAA).
  • • Under 21 CFR 50.25(c), the following statement must be reproduced word-for-word in informed consent documents for applicable clinical trials: “A description of this clinical trial will be available on, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.” Additional information can be provided but changes cannot be made to the statement.
The requirements can apply to foreign clinical trials if the clinical trial is an applicable clinical trial as defined by FDAAA.

Lisa Murtha, Esq., Partner,

  • • The FDA Informed Consent Reporting requirements will need to be monitored on an ongoing basis and the Research Compliance Department is well-suited to provide this monitoring and oversight.
  • • The Research Compliance Department should develop a training module to allow for training of PIs and research administrative, and IRB staff alike so that they fully understand the requirements of the regulations and how to effectively implement those requirements.
  • • The Research Compliance Team must develop a plan to monitor compliance with these requirements including audits of Informed Consent documents to ensure that the applicable language is in place, and monitoring of to validate that the appropriate reporting is accurate and timely.

Harry Nelson, Co-Founder,
Fenton Nelson

  • • Although the 2012 FDA revision to informed consent requirements is on its face fairly minor and technical, it reflects a more significant and substantive trend towards leveraging the as a vehicle for greater transparency in clinical research.
  • • Clinical research compliance programs should be attuned not only to minimal compliance with FDA consent requirements, but also the need for meaningful disclosure of risks in a manner that increases the integrity of the informed consent process.

FDA/Office of Policy
Jarilyn Dupont
Director of Regulatory Policy
speaker bio »»

Lisa Murtha, Esq.
speaker bio »»

Fenton Nelson
Harry Nelson
speaker bio »»

Who Should Attend?

- FDA Attorneys
- Legal Executive
- Health Care Law Attorneys
- Health Industry Advisors
- Health Policy Directors
- Compliance Officers
- State Health Executives/Professionals
- General Counsel
- Senior Management
- Senior Executives
- Professionals coming from Food and Drug Industries
- Consultants & Clients in the Food and Drug Industries

Why Attend?

This is a must attend event for food and drug professionals who would like to learn and understand the new consent requirement including its impact to the industry.

- Guidance and best practices regarding reading & interpreting financial statements
- Hear directly from key regulators & thought leaders
- Interact directly with panel during Q&A

Register and be in the know! Enroll in this course today by clicking the “Register” button below. Discounts apply to those who register in advance!

Registration Information:                                                                                                                                    

(Click here for information on group registrations and discounts)

Please note, the event date is firm although it may be subject to change. Please click here for details.
The Knowledge Group, LLC is producing this event for information purposes only. We do not intend to provide or offer business advice. The contents of this event are based upon the opinions of our speakers. The Knowledge Congress does not warrant their accuracy and completeness. The statements made by them are based on their independent opinions and does not necessarily reflect that of The Knowledge Congress' views. In no event shall The Knowledge Congress be liable to any person or business entity for any special, direct, indirect, punitive, incidental or consequential damages as a result of any information gathered from this webcast.





Legal Series: Understanding FDA’s Consent Form Requirements
LIVE Webcast
Speaker Firms:

FDA/Office of Policy

SNR Denton is a client-focused international legal practice delivering quality and value. We serve clients in key business and financial centers from more than 60 locations worldwide, through offices, associate firms and special alliances across the US, UK, Europe, the Middle East, Russia and the CIS, Asia Pacific and Africa, making us a top 25 legal services provider by lawyers and professionals. Joining the complementary top tier practices of its founding firms – Sonnenschein Nath & Rosenthal LLP and Denton Wilde Sapte LLP – SNR Denton offers business, government and institutional clients premier service and a disciplined focus to meet evolving needs in eight key industry sectors: Financial Institutions and Funds (including derivatives); Energy, Transport and Infrastructure; Government; Health and Life Sciences; Insurance; Manufacturing; Real Estate, Retail and Hotels; and Technology, Media and Telecommunications. For more information, visit

Fenton Nelson represents healthcare providers, including healthcare professionals, facilities, and other organizations, in litigation, business transactions, and regulatory matters. Although we are based in California, our practice is national in scope.

As a result of our landmark victories on behalf of California providers over the past 25 years, we have earned a reputation as a "go-to" firm for healthcare matters. Fenton Nelson is the only boutique firm in California to receive a Top-Tier Firm rating in regulatory and administrative law from U.S. News & World Report. Fenton Nelson attorneys defend healthcare providers in investigations before the Medicare Program and its contractors, the FDA, and the widest range of other federal and state regulatory agencies. The firm has tried cases and argued to the California Supreme Court on fraud and abuse, peer review, reimbursement, and healthcare administrative issues, and we negotiated a broad range of transactions for healthcare providers. The firm also provides counsel in transactional and compliance matters to enable clients to achieve their business objectives, implements compliance programs, and oversees compliance as outside counsel for hospitals, long-term and behavioral healthcare organizations, and life sciences companies.

Clients rely on our detailed knowledge and deep understanding of the complexities of the healthcare industries, from the widest range of physician organizations to skilled nursing facilities, medical device companies, hospice and home health providers, drug treatment, autism care, and countless other niches of healthcare practice. We make it our business to be up to date in the regulatory requirements with which firm clients are required to comply and to give strategic advice on the direction of change ahead. As a result, we are able to offer smart, effective counsel and representation in a manner that is highly responsive, efficient, and strategic


The Knowledge Group, LLC is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be addressed to the National Registry of CPE Sponsors, 150 Fourth Avenue North, Suite 700, Nashville, TN, 37219-2417. Website:


We are an approved multi-event sponsor in the state of California. Our provider ID is: 14451. In Texas, Illinois, and Virginia, we submit programs for individual approval in advance. In all other states, once attendance is verified, participants are emailed an official certificate of attendance which they submit to their respective State Bar Associations. Our programs are created with continuing education in mind and are therefore designed to meet the requirements of State Bar Associations. The State Bars will have the final determination on whether to provide credit or not. If you have any questions, please email our CLE coordinator at:

Attention New York Attorneys:

This program is approved for CLE credit under New York’s Approved Jurisdiction policy. The Knowledge Group, LLC is an approved sponsor in the state of California, a New York Approved Jurisdiction. This program fulfills the non-traditional format requirement of exceeding 60 minutes in length. Please note only experienced attorneys (more than 2 years) are eligible to receive CLE credit via non-traditional format learning platforms. The Knowledge Group will verify attendance during the webcast via secret words (3 per credit hour) and by auditing attendees log in and log out records. All verification instructions will be provided during the webcast. Once attendance verification requirements have been completed, the attendee will be issued a certificate of attendance be The Knowledge Group for the course with the recommended number of credit hours. The Certificate of Attendance is normally sent via email in 24 hours or less.

To Claim Your CLE Credits:

The attorney should simply include credits earned via Knowledge Group webcasts when computing the total number of CLE credits completed, and keep the Knowledge Group Certificate of Attendance for a period of at least four (4) years in case of audit. An attorney may count towards her/his New York CLE requirement credit earned through the Approved Jurisdiction policy without notifying the CLE Board.

To learn more about New York’s Approved Jurisdiction policy. Please visit:

Attention Pennsylvania Attorneys:

Knowledge Congress is not yet an Accredited Distance Learning Provider in PA, neither the instructors nor any PA attendees will receive credit for the course.

Enrolled Agents Sponsor ID Number: 7602U

We have entered into an agreement with the Office of Professional Responsibility, Internal Revenue Service, to meet the requirements of 31 Code of Federal Regulations, section 10.6(g), covering maintenance of attendance records, retention of program outlines, qualifications of instructors, and length of class hours. This agreement does not constitute an endorsement by the Office of Professional Responsibility as to the quality of the program or its contribution to the professional competence of the enrolled individual.